LXX Chart by TradingView

Business Description

Lexaria Bioscience Corp. (“Lexaria”, “Company”) is a life sciences company that has recently received patent protection for their DehydraTECH™ technology from the U.S. Patent and Trademark Office.

Website: https://www.lexariabioscience.com/

FRC Analyst's Reports

Lexaria Bioscience (CSE: LXX) Focus Seemingly on R&D as Licensing Revenues Slow May. 7, 2019
Lexaria Bioscience (CSE: LXX) Landmark Partnership with Tobacco Titan Feb. 5, 2019
Lexaria (CSE: LXX) Additional Licensees and Expanded IP Aug. 31, 2018
Lexaria (OTCQX: LXRP / CSE: LXX) Initial Cannabis Focus; Multi-Market Potential Jan. 12, 2018


Lexaria Appoints New Board Member Jan. 15, 2021
Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants Jan. 15, 2021
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Jan. 12, 2021
Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH Dec. 22, 2020
Lexaria Closes Sale of Non-Pharmaceutical THC-Related Assets Dec. 10, 2020